6 results about "Lymphatic metastasis" patented technology

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.

The invention discloses an early gastric cancer lymphatic metastasis risk auxiliary inspection method based on collagen fiber morphological structure fusion characteristics. An extracellular matrix collagenous fiber image of a gastric tumor tissue is obtained in an unmarked second harmonic imaging mode, and automatic early gastric cancer lymphatic metastasis risk assessment can be realized by performing quantitative calculation and analysis of multivariate parameter characteristics on morphological structure characteristics of the collagenous fiber. According to the method, the morphological structure characteristics of the gastric tumor collagenous fibers can be intuitively displayed through a pixel-level morphological characterization method, and the information readability is enhanced. According to the method, the complementarity of the morphological structure characteristics of the collagenous fibers of the gastric tumor tissue is remarkably improved through multi-element parameter characteristic characterization, and the accuracy of lymphatic metastasis risk assessment is further improved. According to the method, an early gastric cancer lymphatic metastasis risk specificity index is formed based on the multi-element morphological characteristics of collagenous fibers, and a local focus area can be quantitatively and intuitively displayed.

This invention discloses the application of lncRNA MAGE-A10-encoded short peptide in regulating lymph node metastasis and targeted therapy in bladder cancer, belonging to the field of biomedical technology. This invention focuses on the coding ability of long non-coding RNAs, using high-throughput sequencing and bioinformatics algorithms to screen for lncRNA MAGE-A10, which is highly expressed in lymph node metastasis-positive bladder cancer tissues. The coding ability was verified by predicting open reading frames, constructing expression vectors, and synthesizing specific antibodies. The encoded short peptide MAGE-A10-44aa was positively correlated with lymph node metastasis in bladder cancer and poor patient prognosis, and also promoted lymphangiogenesis and lymph node metastasis in bladder cancer. This confirms the biological role of the MAGE-A10-44aa short peptide in bladder cancer lymph node metastasis, providing a potential target for bladder cancer treatment.

The invention discloses an FELDI nano-particle chip kit and application thereof in screening metabolic marker combinations, and relates to the technical field of biology. The FELDI nano-particle chip kit comprises a methanol solution and a microarray chip which is pre-coated with iron nano-particles, the kit is used for dewaxing tissue slices, the tissue slices are immersed in a methanol solution and incubated to obtain a sample, and the sample is applied to a microarray chip pre-coated with iron nanoparticles; a colorectal cancer tissue metabolism fingerprint database is constructed, and specific metabolism markers combined with L-cysteine, adipic acid, decanoic acid, azelaic acid, pentadecanoic acid, stearic acid and isolithocholic acid are screened. The invention develops an unmarked iron nanoparticle enhanced laser desorption ionization mass spectrometry technology platform, and the small molecule metabolites can be directly and efficiently captured and ionized from the formalin-fixed paraffin-embedded CRC primary tissue section. And screening out a specific small molecule metabolism marker combination for distinguishing lymphatic metastasis and non-metastasis.